Growth & Buyout Acquisitions & Partnerships

SWIXX signs distribution contract with Albireo for Bylvay

Thursday 4 November, 2021

Bylvay was approved in the US and the EU as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older. PFIC is a rare and devastating disorder affecting young children that causes progressive, life-threatening liver disease. Until the advent of Bylvay, the only option for patients for surgery.